It is interestingly to speculate that the patient with the Tel-Lyn fusion could have benefited from treatment with second or third generation CML drugs (e.g. Dasatinib), which are highly potent Lyn kinase inhibitors, instead of the Immatinib therapy they received prior to succumbing to their disease. Here, LYN is linked to chronic myelogenous leukemia, BCR-ABL1 positive.